|
- Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Aldosterone dysregulation contributes to hypertension Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited
- Lorundrostat reduces systolic blood pressure in CKD, hypertension - Healio
HOUSTON — The investigational aldosterone synthase inhibitor lorundrostat demonstrated efficacy in reducing systolic blood pressure and albuminuria for patients with uncontrolled hypertension
- Lorundrostat - Wikipedia
Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure
- Lorundrostat Lowers Blood Pressure Compared with Placebo at 12 Weeks
Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC 25)
- Lorundrostat in Participants With Uncontrolled Hypertension and . . .
Lorundrostat, a novel aldosterone synthase inhibitor that reduces aldosterone production, demonstrated efficacy in participants with uncontrolled hypertension, including those with treatment-resistant hypertension
- Clinical Trial Shows Drug Developed to Treat Uncontrolled Hypertension . . .
Findings from a clinical trial led by a Cleveland Clinic cardiologist showed that lorundrostat – a new type of blood pressure medication — safely decreased blood pressure in patients with uncontrolled hypertension
- HIGHLY EFFECTIVE BLOOD PRESSURE LOWERING WITH LORUNDROSTAT, A NEW . . .
Based on these findings, development of lorundrostat has progressed; a Phase 2 safety and dose-ranging trial in subjects with hypertension has been completed and a pivotal registration program is anticipated to begin in 2023
- Efficacy and safety of lorundrostat in uncontrolled . . . - Springer
Hypertension remains a leading global health concern, contributing significantly to cardiovascular and renal morbidity and mortality This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat, a selective aldosterone synthase inhibitor, in adults with uncontrolled hypertension, synthesizing evidence from randomized controlled trials We systematically
|
|
|